Date:6/17/2009

uld cause actual results to differ materially from the conclusion, forecast or projection in the forward-looking information, and (ii) the material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, is contained in the Company's annual report and other documents filed from time to time with the Canadian securities commissions which are available at www.sedar.com. These statements speak only as of the date they are made, and we assume no obligation to revise such statements as a result of any event, circumstance or otherwise, except in accordance with law.

'/>"/>

SOURCE BioSyntech, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
2. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
3. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
4. Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
5. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
6. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
7. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
8. Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
9. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business